Skip to main content

Table 2 Absolute change in the endpoints after 12 weeks of therapy

From: Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial

 

Dapagliflozin

Glibenclamide

p

Posttreatment change in the Rest FMD at 1 min, %

3.3 (8.2)

− 1.2 (7.5)

0.0001

Posttreatment change in the Post I/R FMD at 1 min, %

2.1 (9.4)

− 0.4 (11.1)

0.264

Posttreatment change in the AUC of arterial diameter during the 5-min course of Rest FMD, mm

0.5 ± 3.5

− 0.3 ± 3.5

0.001

Posttreatment change in the peak of systolic velocity, cm/sec

   

 At baseline

3.6 (39.9)

− 0.41 (29.8)

0.0001

 At 1-min

6.7 (49.5)

− 2.3 (49.1)

0.0001

 At 5-min

6.3 (32.3)

− 2.6 (47.0)

0.0001

Posttreatment change in the end diastolic velocity, cm/sec

   

 At baseline

− 0.13 (4.01)

− 0.12 (4.52)

0.387

 At 1-min

− 0.02 (8.89)

− 1.15 (8.42)

0.001

 At 5-min

0.77 (3.85)

− 0.51 (3.58)

0.0001

Posttreatment change in the resistive index

   

 At baseline

0.009 (0.06)

0.006 (0.07)

0.135

 At 1-min

− 0.01 (0.12)

0.01 (0.10)

0.0001

 At 5-min

− 0.02 (0.07)

0.01 (0.07)

0.0001

Posttreatment change in Nitrate levels during FMD, nmol/L

   

 At baseline

3.2 (16)

2.1 (10)

0.26

 At 1-min

3.3 (17)

0.9 (18)

0.14

 At 5-min

1.2 (10)

0.1 (14)

0.20

 AUC during the 5-min course

5.6 (25)

2.2 (29)

0.15

Posttreatment change in Nitrite levels during FMD, nmol/L

   

 At baseline

0.013 (0.10)

0.019 (0.11)

0.135

 At 1-min

0.031 (0.18)

0.009 (0.10)

0.0001

 At 5-min

0.006 (0.07)

0.0013 (0.07)

0.0001

 AUC during the 5-min course

0.18 (0.24)

0.01 (0.15)

0.0001